Eli Lilly and Company (LLY) — Analyst outlook / Analyst consensus target is. Based on 45 analyst ratings, the consensus is bullish — 33 Buy, 9 Hold, 3 Sell.
The consensus price target is $1,243.95 (low: $985.00, high: $1,350.00), representing an upside of 34.8% from the current price $922.50.
Analysts estimate Earnings Per Share (EPS) of $12.83 and revenue of $45.10B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $11.76 vs est $12.83 (missed -8.4%). 2025: actual $23.00 vs est $23.59 (missed -2.5%). Analyst accuracy: 94%.
LLY Stock — 12-Month Price Forecast
$1,243.95
▲ +34.85% Upside
Average Price Target
Based on 45 Wall Street analysts offering 12-month price targets for Eli Lilly and Company, the average price target is $1,243.95, with a high forecast of $1,350.00, and a low forecast of $985.00.
The average price target represents a +34.85% change from the last price of $922.50.
Highest Price Target
$1,350.00
Average Price Target
$1,243.95
Lowest Price Target
$985.00
LLY Analyst Ratings
Buy
Based on 45 analysts giving stock ratings to Eli Lilly and Company in the past 3 months
EPS Estimates — LLY
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $11.76
vs Est $12.83
▼ 9.1% off
2025
Actual $23.00
vs Est $23.59
▼ 2.6% off
Profitability Outlook
Strong profitability with high earnings per share. EPS trend is improving.
Revenue Estimates — LLY
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $45.043B
vs Est $45.102B
▼ 0.1% off
2025
Actual $65.179B
vs Est $63.861B
▲ 2.0% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
